Currently browsing tag


FDA approves Baxalta’s drug for rare bleeding disorder

(Reuters) – The U.S. Food and Drug Administration said on Friday it approved Baxalta Inc's drug for use in patients with a type of rare bleeding disorder. The drug, Adynovate, was approved to control and reduce the frequency of bleeding episodes in patients with Hemophilia A, the agency said in a statement. Data from a late-stage study, which tested 137 patients, showed that Adynovate was effective in reducing and controlling bleeding episodes, compared with Advate.

Volkswagen to halt U.S. sales of some 2015 diesel cars

FRANKFURT/HAMBURG (Reuters) – Volkswagen told U.S. dealers to halt sales of some 2015 diesel cars after regulators found software it designed for the affected vehicles gave false emissions data, the company said Sunday, announcing it had launched an investigation. In a statement published by the carmaker on Sunday, Chief Executive Officer Martin Winterkorn said, “I personally am deeply sorry that we have broken the trust of our customers. “Volkswagen has ordered an external investigation of this matter,” he said.

Novartis hit by China, emerging market slowdown: CEO on CNBC

Drugmaker Novartis has been hit by a slowdown in emerging markets, particularly in China, where previously double-digit growth has decelerated to mid-single digits, Chief Executive Joe Jimenez said in an interview with CNBC on Friday. Jimenez' comments echoed concerns expressed on Thursday by U.S. Federal Reserve Chair Janet Yellen, who said the outlook in emerging markets including China have led to volatility. Despite the increasing risks, Jimenez said the Swiss company was not pulling back from emerging markets, rather relying on the strength of generics in China to drive business growth.

CGI exiting low-margin markets, eyes M&A in cyber security

By Alastair Sharp TORONTO (Reuters) – CGI Group Inc , the information systems and management consultancy, said on Wednesday it would target acquisitions in cyber security while exiting some markets entirely, as it reported third-quarter profit and revenue that missed estimates. The company's chief executive officer said it has compiled a short list of 85 potential acquisition targets that would help it grow by delving deeper into industries, three years after going wide with its Logica acquisition. CEO Michael Roach told investors on a conference call that the company is working its way through a list compiled from almost a thousand interviews with top managers at its customers “as part of our buy strategy.” Scores of acquisitions have fueled CGI's growth over four decades.